πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 29,054 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11814444

Cyclic polypeptides for PCSK9 inhibition

RA PHARMACEUTICALS, INC. Β· Granted Tue Nov 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11814440

Glypican 2 as a cancer marker and therapeutic target

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Nov 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11814439

Anti-CD20 antibody compositions

TG Therapeutics, Inc. Β· Granted Tue Nov 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11814431

B7-H4 antibodies and methods of use thereof

Five Prime Therapeutics, Inc. Β· Granted Tue Nov 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11814428

Anti-PTCRA antibody-drug conjugates and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Nov 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11814427

Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a s

Rani Therapeutics, LLC Β· Granted Tue Nov 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11814410

Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereo

CytomX Therapeutics, Inc. Β· Granted Tue Nov 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11814394

Exatecan derivatives, linker-payloads, and conjugates and thereof

GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. Β· Granted Tue Nov 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11814377

Pyrimidine compound as JAK kinase inhibitor

Theravance Biopharma R&D IP, LLC Β· Granted Tue Nov 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11814373

Methods and compounds for restoring mutant p53 function

PMV PHARMACEUTICALS, INC. Β· Granted Tue Nov 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11814371

Heterocyclic compound

Medshine Discovery Inc. Β· Granted Tue Nov 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11813123

Ultrasound responsive micro-composite markers

The Regents of the University of California Β· Granted Tue Nov 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11813235

Guanfacine as an anti-virulence agent

THE TRUSTEES OF PRINCETON UNIVERSITY Β· Granted Tue Nov 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11814432

Anti-HLA-A2 antibodies, related chimeric antigen receptors, and uses thereof

SANGAMO THERAPEUTICS FRANCE Β· Granted Tue Nov 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11813257

Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital

Disc Medicine, Inc. Β· Granted Tue Nov 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11813310

Long-acting G-CSF for preventing neutropenia or reducing duration of neutropenia

ILKOGEN ILAÇ SANAYI VE TICARET A.S. · Granted Tue Nov 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11813319

Development of a novel live attenuated African Swine Fever vaccine based in the deletion o

The United States of America, as represented by the Secretary of Agriculture Β· Granted Tue Nov 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11813335

Pyrrolobenzodiazepine-antibody conjugates

ADC THERAPEUTICS SA Β· Granted Tue Nov 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11813357

Treatment of hip pain with sustained-release liposomal anesthetic compositions

Pacira Pharmaceuticals, Inc. Β· Granted Tue Nov 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11814376

Hepatitis b core protein modulators

ASSEMBLY BIOSCIENCES, INC. Β· Granted Tue Nov 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11814624

Targeted non-viral DNA insertions

The Regents of the University of California Β· Granted Tue Nov 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11806336

Methods and compositions for treatment of epileptic disorders

OVID THERAPEUTICS INC. Β· Granted Tue Nov 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11806318

Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflamma

THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Tue Nov 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11806360

Compositions and methods for treating transthyretin (TTR) mediated amyloidosis

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Nov 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted